Filing Details
- Accession Number:
- 0000919574-10-002693
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-03-22 13:00:00
- Reporting Period:
- 2010-03-18
- Filing Date:
- 2010-03-22
- Accepted Time:
- 2010-03-22 16:51:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1068796 | Maxygen Inc | MAXY | Services-Commercial Physical & Biological Research (8731) | 770449487 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1174784 | Conus Partners Inc | 49 West 38Th Street 11Th Floor New York NY 10018 | No | No | Yes | No | |
| 1437688 | Andrew Zacks | 49 West 38Th Street 11Th Floor New York NY 10018 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-03-18 | 4,420 | $6.05 | 3,131,530 | No | 4 | S | Indirect | See Footnote |
| Common Stock | Disposition | 2010-03-22 | 40,300 | $5.85 | 3,091,230 | No | 4 | S | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See Footnote |
| No | 4 | S | Indirect | See Footnote |
Footnotes
- The price reported above reflects a weighted average sale price. These shares of Common Stock (the "Shares") of Maxygen, Inc. (the "Issuer") were sold in multipletransactions at prices ranging from $6 to $6.07, inclusive. Conus Partners, Inc. and Andrew Zacks (the "Reporting Persons") undertake to provide to any securityholder of the Issuer or to the SEC, upon request, full information regarding the number of Shares sold at each separate price within the range stated.
- These Shares are held in the accounts of private investment vehicles and certain managed accounts over which each Reporting Person has investment discretion.Conus Partners, Inc. has investment discretion over the Shares because it is the investment adviser to such private investment vehicles and managed accounts.Andrew Zacks has investment discretion over the Shares because he is the managing director of Conus Partners, Inc.
- The price reported above reflects a weighted average sale price. These Shares were sold in multiple transactions at prices ranging from $5.85 to $5.87, inclusive.The Reporting Persons undertake to provide to any security holder of the Issuer or to the SEC, upon request, full information regarding the number of Shares sold ateach separate price within the range stated.
Billionaire Hedge Funds
